DFTX

#1289
Definium Therapeutics, Inc. - Common Shares
40.9 8 USD
-0.06%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
40.98
40.98
Intervallo Annuale
14.62
49.70
Variazione giornaliera
-6.48%
Variazione Mensile
-8.89%
Variazione di 6 mesi
+144.51%
Variazione Annuale
+171.21%
Chiusura Precedente
43.8 2
Open
40.9 8
Minimo
40.9 8
Massimo
40.9 8
Volume
196
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Definium Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Definium Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Definium Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K

Definium Therapeutics, Inc. current report, Q1 FY2026

Full document

Definium Therapeutics, Inc. (DFTX) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed on January 9, 2026, by Definium Therapeutics, Inc., formerly known as Mind Medicine (MindMed) Inc. The filing covers corporate actions taken on January 9, 2026, and financial updates as of December 31, 2025. The Company is incorporated in British Columbia and trades on The Nasdaq Stock Market.

Key Financial Metrics

  • Liquidity: The Company disclosed estimated preliminary cash, cash equivalents, and investments of approximately $412 million as of December 31, 2025.
  • Audit Status: This financial information is unaudited, preliminary, and subject to completion. KPMG LLP has not audited or reviewed these figures.
  • Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt levels.

Material Changes

  • Corporate Name Change: The Company officially changed its name from "Mind Medicine (MindMed) Inc." to "Definium Therapeutics, Inc." effective January 9, 2026.
  • Trading Symbol: Common shares will trade under the new ticker symbol "DFTX" starting at market open on January 13, 2026. The CUSIP number remains unchanged.
  • Strategic Positioning: The rebranding reflects a transition into the next phase of development, positioning the Company as a leader in psychiatric drug development.

Outlook, Risks, and Management Commentary

Management stated that the rebranding aligns with the Company's strategic evolution. No specific forward-looking guidance regarding revenue or clinical milestones was included in this specific filing. The primary risk noted is that the preliminary cash position of $412 million is unaudited and may vary from the actual financial position upon final audit.

Investor Verification Checklist

  • Verify the trading symbol change to "DFTX" on January 13, 2026.
  • Confirm the final audited cash, cash equivalents, and investment balances in the upcoming 10-K filing, as the $412 million figure is preliminary.
  • Review the attached Corporate Presentation (Exhibit 99.2) for additional strategic details not fully elaborated in the 8-K text.
  • Monitor for any shareholder action requirements, though the filing states none are required for this name change.